A Pharmacological Profile of Ribavirin and Monitoring of its Plasma Concentration in Chronic Hepatitis C Infection

Journal of Clinical and Experimental Hepatology

Volumn 2 1, Issue 1, 2012, Pages 42-54

  Naik, Girish S ^a   Tyagi, Manoj G ^a  

^a CHRISTIAN MEDICAL COLLEGE   (India)

Author keywords

HCV; Plasma concentration; Ribavirin; TDM

Indexed keywords

ALPHA INTERFERON; BOCEPREVIR; INOSINE TRIPHOSPHATE; INTERFERON; PEGINTERFERON; PEGINTERFERON ALPHA; RIBAVIRIN; TELAPREVIR;

ANEMIA; ANTIVIRAL ACTIVITY; AREA UNDER THE CURVE; BACTERIAL PNEUMONIA; BONE DENSITY; BRONCHOSPASM; COMBINATION CHEMOTHERAPY; DISEASE ASSOCIATION; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG ACCUMULATION; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DETERMINATION; DRUG DISTRIBUTION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MONITORING; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; ECZEMA; HEMOLYSIS; HEMOLYTIC ANEMIA; HEPATITIS C; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOXIA; KIDNEY DISEASE; LIVER TRANSPLANTATION; LOW DRUG DOSE; LUNG EDEMA; MAXIMUM PLASMA CONCENTRATION; MIXED INFECTION; MONOTHERAPY; NAUSEA; NONHUMAN; PHARYNGITIS; PRIORITY JOURNAL; PRURITUS; REVIEW; RIGOR; RISK FACTOR; SIDE EFFECT; TERATOGENICITY; TREATMENT DURATION;

EID: 84859851553     PISSN: 09736883     EISSN: 22133453     Source Type: Journal    
DOI: 10.1016/S0973-6883(12)60090-5     Document Type: Review

References (90)

1. Lavanchy D The global burden of hepatitis C. Liver Int 2009, 29:74-81.
2. Shepard CW, Finelli L, Alter MJ Global epidemiology of hepatitis C virus infection. The Lancet Infectious Dis 2005, 5:558-567.
3. Hepatitis C - Chapter 3 - 2012 Yellow Book - Travelers' Health - CDC http://wwwnc.cdc.gov/travel/yellowbook/2012/chapter-3-infectious-diseases-related-to-travel/hepatitis-c.htm.
4. Armstrong GL, Wasley A, Simard EP, et al. The prevalence of hepatitis C virus infection in the United States, 1999 through 2002. Ann Intern Med 2006, 144:705-714.
5. National Institutes of Health Consensus Development Conference Statement: management of hepatitis C 2002 (June 10-12, 2002). Gastroenterology 2002, 123:2082-2099.
6. Mchutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
7. Singh S, Malhotra V, Sarin SK Distribution of hepatitis C virus genotypes in patients with chronic hepatitis C infection in India. Indian J Med Res 2004, 119:145-148.
8. Rehan HS, Manak S, Yadav M, Chopra D, Wardhan N Diversity of genotype and mode of spread of Hepatitis C virus in Northern India. Saudi J Gastroenterol 2011, 17:241-244.
9. Sievert W, Altraif I, Razavi HA, et al. A systematic review of hepatitis C virus epidemiology in Asia, Australia and Egypt. Liver Int 2011, 31(Suppl 2):61-80.
10. Flamm SL Chronic hepatitis C virus infection. JAMA 2003, 289:2413-2417.
11. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon Alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
12. Manns MP, Mchutchison JG, Gordon SC, et al. Peginterferon alfa-2b plus ribavirin compared with interferon alfa-2b plus ribavirin for initial treatment of chronic hepatitis C: a randomised trial. Lancet 2001, 358:958-965.
13. Vermehren J, Sarrazin C New hepatitis C therapies in clinical development. Eur J Med Res 2011, 16:303-314.
14. Brochot E, Castelain S, Duverlie G, et al. Ribavirin monitoring in chronic hepatitis C therapy: anaemia versus efficacy. Antivir Ther (Lond) 2010, 15:687-695.
15. Reddy KR, Nelson DR, Zeuzem S Ribavirin: current role in the optimal clinical management of chronic hepatitis C. J Hepatol 2009, 50:402-411.
16. Leyssen P, Balzarini J, De Clercq E, Neyts J The predominant mechanism by which ribavirin exerts its antiviral activity in vitro against flaviviruses and paramyxoviruses is mediated by inhibition of IMP dehydrogenase. J Virol 2005, 79:1943-1947.
17. Hong Z, Cameron CE Pleiotropic mechanisms of ribavirin antiviral activities. Prog Drug Res 2002, 59:41-69.
18. Atsukawa M, Nakatsuka K, Kobayashi T, et al. Ribavirin down-modulates ICOS on CD4 + T-cells and their interleukin-10 secretion to assist clearance of hepatitis C virus. J Gastroenterol Hepatol http://onlinelibrary.wiley.com/doi/10.1111/j.1440-1746.2011.06882.x/abstract.
19. Brok J, Gluud LL, Gluud C Ribavirin monotherapy for chronic hepatitis C. Cochrane Database Syst Rev 2009, CD005527.
20. Dixit NM, Layden-Almer JE, Layden TJ, Perelson AS Modelling how ribavirin improves interferon response rates in hepatitis C virus infection. Nature 2004, 432:922-924.
21. Hofmann WP, Chung TL, Osbahr C, et al. Impact of ribavirin on HCV replicon RNA decline during treatment with interferon-a and the protease inhibitors boceprevir or telaprevir. Antivir Ther (Lond) 2011, 16:695-704.
22. Hézode C, Forestier N, Dusheiko G, et al. Telaprevir and peginterferon with or without ribavirin for chronic HCV infection. N Engl J Med 2009, 360:1839-1850.
23. Mchutchison JG, Manns MP, Muir AJ, et al. Telaprevir for previously treated chronic HCV infection. N Engl J Med 2010, 362:1292-1303.
24. Kwo PY, Lawitz EJ, Mccone J, et al. Efficacy of boceprevir, an NS3 protease inhibitor, in combination with peginterferon alfa-2b and ribavirin in treatment-naive patients with genotype 1 hepatitis C infection (SPRINT-1): an open-label, randomised, multicentre phase 2 trial. Lancet 2010, 376:705-716.
25. Fried MW, Shiffman ML, Reddy KR, et al. Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. N Engl J Med 2002, 347:975-982.
26. Fried MW Side effects of therapy of hepatitis C and their management. Hepatology 2002, 36(5 Suppl 1):S237-S244.
27. Takaki S, Tsubota A, Hosaka T, et al. Factors contributing to ribavirin dose reduction due to anemia during interferon alfa2b and ribavirin combination therapy for chronic hepatitis C. J Gastroenterol 2004, 39:668-673.
28. Ribavirin Official FDA information, side effects and uses http://www.drugs.com/pro/ribavirin.htmli4i_section_id_45eff788-cdd0-4e03-947e-14dfae157197.
29. Russo MW, Fried MW Side effects of therapy for chronic hepatitis C. Gastroenterology 2003, 124:1711-1719.
30. Mchutchison JG, Gordon SC, Schiff ER, et al. Interferon alfa-2b alone or in combination with ribavirin as initial treatment for chronic hepatitis C. Hepatitis Interventional Therapy Group. N Engl J Med 1998, 339:1485-1492.
31. Sung H, Chang M, Saab S Management of hepatitis C antiviral therapy adverse effects. Curr Hepat Rep 2011, 10:33-40.
32. Copegus 200mg and 400mg Film-coated Tablets-Summary of Product Characteristics (SPC)-Electronic Medicines Compendium (emc).
33. Solís-Herruzo JA, Castellano G, Fernández I, Muñoz R, Hawkins F Decreased bone mineral density after therapy with alpha interferon in combination with ribavirin for chronic hepatitis C. J Hepatol 2000, 33:812-817.
34. Fisher-Hoch SP, Gborie S, Parker L, Huggins J Unexpected adverse reactions during a clinical trial in rural west Africa. Antiviral Res 1992, 19:139-147.
35. Ribavirin Side Effects . Available at: . http://www.drugs.com/sfx/ribavirin-side-effects.html.
36. De Franceschi L, Fattovich G, Turrini F, et al. Hemolytic anemia induced by ribavirin therapy in patients with chronic hepatitis C virus infection: role of membrane oxidative damage. Hepatology 2000, 31:997-1004.
37. Hitomi Y, Cirulli ET, Fellay J, et al. Inosine triphosphate protects against ribavirin-induced adenosine triphosphate loss by adenylosuccinate synthase function. Gastroenterology 2011, 140:1314-1321.
38. Tanaka H, Miyano M, Ueda H, Fukui K, Ichinose M Changes in serum and red blood cell membrane lipids in patients treated with interferon ribavirin for chronic hepatitis C. Clin Exp Med 2005, 5:190-195.
39. Van Soest H, Renooij W, van Erpecum KJ Clinical and basal aspects of anemia during antiviral therapy for hepatitis C. Ann Hepatol 2009, 8:316-324.
40. Grattagliano I, Russmann S, Palmieri VO, et al. Glutathione peroxidase, thioredoxin, and membrane protein changes in erythrocytes predict ribavirin-induced anemia. Clin Pharmacol Ther 2005, 78:422-432.
41. Reau N, Hadziyannis SJ, Messinger D, Fried MW, Jensen DM Early predictors of anemia in patients with hepatitis C genotype 1 treated with peginterferon alfa-2a (40KD) plus ribavirin. Am J Gastroenterol 2008, 103:1981-1988.
42. Hung C, Lee C, Lu S, et al. Anemia associated with antiviral therapy in chronic hepatitis C: incidence, risk factors, and impact on treatment response. Liver Int 2006, 26:1079-1086.
43. Van Vlierberghe H, Delanghe JR, De Vos M, Leroux-Roel G Factors influencing ribavirin-induced hemolysis. J Hepatol 2001, 34:911-916.
44. Grattagliano I, Russmann S, Palmieri VO, et al. Low membrane protein sulfhydrils but not G6PD deficiency predict ribavirin-induced hemolysis in hepatitis C. Hepatology 2004, 39:1248-1255.
45. COPEGUS® (ribavirin, USP) TABLETS http://dailymed.nlm.nih.gov/dailymed/archives/fdadruginfo.cfm?Archiveid=20082.
46. Preston SL, Drusano GL, Glue P, et al. Pharmacokinetics and absolute bioavailability of ribavirin in healthy volunteers as determined by stable-isotope methodology. Antimicrob Agents Chemother 1999, 43:2451-2456.
47. Wade JR, Snoeck E, Duff F, Lamb M, Jorga K Pharmacokinetics of ribavirin in patients with hepatitis C virus. Br J Clin Pharmacol 2006, 62:710-714.
48. Yamamoto T, Kuniki K, Takekuma Y, et al. Ribavirin uptake by cultured human choriocarcinoma (BeWo) cells and Xenopus laevis oocytes expressing recombinant plasma membrane human nucleoside transporters. Eur J Pharmacol 2007, 557:1-8.
49. Yamamoto T, Sugawara M, Kikukawa T, et al. Kinetic study of antiviral ribavirin uptake mediated by hcnt3 and hent1 in Xenopus laevis oocytes. Biophys Chem 2010, 147:59-65.
50. Morello J, Rodríguez-Novoa S, Jiménez-Nácher I, Soriano V Usefulness of monitoring ribavirin plasma concentrations to improve treatment response in patients with chronic hepatitis C. J Antimicrob Chemother 2008, 62:1174-1180.
51. Loustaud-Ratti V, Alain S, Rousseau A, et al. Ribavirin exposure after the first dose is predictive of sustained virological response in chronic hepatitis C. Hepatology 2008, 47:1453-1461.
52. Morello J, Rodríguez-Nóvoa S, Cantillano ALR, et al. Measurement of ribavirin plasma concentrations by high-performance liquid chromatography using a novel solid-phase extraction method in patients treated for chronic hepatitis C. Ther Drug Monit 2007, 29:802-806.
53. Liu Y, Xu C, Yan R, et al. Sensitive and specific LC-MS/MS method for the simultaneous measurements of viramidine and ribavirin in human plasma. J Chromatogr B Analyt Technol Biomed Life Sci 2006, 832:17-23.
54. Dixit NM, Perelson AS The metabolism, pharmacokinetics and mechanisms of antiviral activity of ribavirin against hepatitis C virus. Cell Mol Life Sci 2006, 63:832-842.
55. Marquet P, Sauvage FL, Loustaud-Ratti V, et al. Stability of ribavirin concentrations depending on the type of blood collection tube and preanalytical conditions. Ther Drug Monit 2010, 32:237-241.
56. Pedersen C, Alsiö Å, Lagging M, et al. Ribavirin plasma concentration is a predictor of sustained virological response in patients treated for chronic hepatitis C virus genotype 2/3 infection. J Viral Hepat 2011, 18:245-251.
57. Morello J, Soriano V, Barreiro P, et al. Plasma ribavirin trough concentrations at week 4 predict hepatitis C virus (HCV) relapse in HIV-HCV-coinfected patients treated for chronic hepatitis C. Antimicrob Agent Chemother 2010, 54:1647-1649.
58. Slavenburg S, Huntjens-Fleuren HWHA, Dofferhoff TSM, et al. Ribavirin plasma concentration measurements in patients with hepatitis C: early ribavirin concentrations predict steady-state concentrations. Ther Drug Monit 2011, 33:40-44.
59. Arase Y, Ikeda K, Tsubota A, et al. Significance of serum ribavirin concentration in combination therapy of interferon and ribavirin for chronic hepatitis C. Intervirology 2005, 48:138-144.
60. Tsubota A, Hirose Y, Izumi N, Kumada H Pharmacokinetics of ribavirin in combined interferon-alpha 2b and ribavirin therapy for chronic hepatitis C virus infection. Br J Clin Pharmacol 2003, 55:360-367.
61. Lindahl K, Stahle L, Bruchfeld A, Schvarcz R High-dose ribavirin in combination with standard dose peginterferon for treatment of patients with chronic hepatitis C. Hepatology 2005, 41:275-279.
62. Maynard M, Pradat P, Gagnieu MC, Souvignet C, Trepo C Prediction of sustained virological response by ribavirin plasma concentration at week 4 of therapy in hepatitis C virus genotype 1 patients. Antivir Ther (Lond) 2008, 13:607-611.
63. Saito H, Tada S, Ebinuma H, et al. Role of erythrocytes as a reservoir for ribavirin and relationship with adverse reactions in the early phase of interferon combination therapy for chronic hepatitis C virus infections. J Clin Microbiol 2006, 44:3562-3568.
64. Muñoz-de-Rueda P, Ruiz-Extremera A, Candel JM, et al. Plasma ribavirin trough concentrations during treatment of chronic hepatitis C in genotype-1 patients. J Clin Gastroenterol 2012, 46:328-333.
65. Lindahl K, Schvarcz R, Bruchfeld A, Ståhle L Evidence that plasma concentration rather than dose per kilogram body weight predicts ribavirin-induced anaemia. J Viral Hepatol 2004, 11:84-87.
66. Maeda Y, Kiribayashi Y, Moriya T, et al. Dosage adjustment of ribavirin based on renal function in Japanese patients with chronic hepatitis C. Ther Drug Monit 2004, 26:9-15.
67. Uchida M, Hamada A, Yamasaki M, et al. Assessment of adverse reactions and pharmacokinetics of ribavirin in combination with interferon alpha-2b in patients with chronic hepatitis C. Drug Metab Pharmacokinet 2004, 19:438-443.
68. Donnerer J, Grahovac M, Stelzl E, et al. Ribavirin levels and haemoglobin decline in early virological responders and non-responders to hepatitis C virus combination therapy. Pharmacology 2006, 76:136-140.
69. Inoue Y, Homma M, Matsuzaki Y, et al. Erythrocyte ribavirin concentration for assessing hemoglobin reduction in interferon and ribavirin combination therapy. Hepatol Res 2006, 34:23-27.
70. KDIGO clinical practice guidelines for the prevention, diagnosis, evaluation, and treatment of hepatitis C in chronic kidney disease. Kidney Int Suppl 2008, S1-99.
71. Gupta SK, Kantesaria B, Glue P Pharmacokinetics, safety, and tolerability of ribavirin in hemodialysis-dependent patients. Eur J Clin Pharmacol 2011. Online First(tm) [Epub ahead of print] http://www.ncbi.nlm.nih.gov/pubmed/22037562.
72. Rendina M, Schena A, Castellaneta NM, et al. The treatment of chronic hepatitis C with peginterferon alfa-2a (40 kda) plus ribavirin in haemodialysed patients awaiting renal transplant. J Hepatol 2007, 46:768-774.
73. Deltenre P, Moreno C, Tran A, et al. Anti-viral therapy in haemodialysed HCV patients: efficacy, tolerance and treatment strategy. Aliment Pharmacol Ther 2011, 34:454-461.
74. Van Leusen R, Adang RPR, de Vries RA, et al. Pegylated interferon alfa-2a (40 kd) and ribavirin in haemodialysis patients with chronic hepatitis C. Nephrol Dial Transpl 2008, 23:721-725.
75. Carriero D, Fabrizi F, Uriel AJ, et al. Treatment of dialysis patients with chronic hepatitis C using pegylated interferon and low-dose ribavirin. Int J Artif Organs 2008, 31:295-302.
76. Bruchfeld A, Wilczek H, Elinder CG Hepatitis C infection, time in renal-replacement therapy, and outcome after kidney transplantation. Transplantation 2004, 78:745-750.
77. Gane E, Pilmore H Management of chronic viral hepatitis before and after renal transplantation. Transplantation 2002, 74:427-437.
78. Rostaing L, Izopet J, Baron E, et al. Treatment of chronic hepatitis C with recombinant interferon alpha in kidney transplant recipients. Transplantation 1995, 59:1426-1431.
79. Gane EJ, Portmann BC, Naoumov NV, et al. Long-term outcome of hepatitis C infection after liver transplantation. N Engl J Med 1996, 334:815-820.
80. Sánchez-Fueyo A, Restrepo JC, Quintó L, et al. Impact of the recurrence of hepatitis C virus infection after liver transplantation on the long-term viability of the graft. Transplantation 2002, 73:56-63.
81. Jain A, Vekatramanan R, Yelochan B, et al. Ribavirin levels in post liver transplant patients treated for recurrent hepatitis c viral infection. Transpl Proc 2005, 37:3190-3196.
82. Dumortier J, Ducos E, Scoazec JY, et al. Plasma ribavirin concentrations during treatment of recurrent hepatitis C with peginterferon alpha-2b and ribavirin combination after liver transplantation. J Viral Hepat 2006, 13:538-543.
83. Lerias de Almeida PR, Alves de Mattos A, Valle Tovo C Sustained virological response according to the type of early virological response in HCV and HCV/HIV. Ann Hepatol 2010, 9:150-155.
84. Crespo M, Pou L, Esteban JI, et al. Early monitoring of ribavirin serum concentration is not useful to optimize hepatitis C virus treatment in HIV-coinfected patients. Antivir Ther (Lond) 2007, 12:1217-1223.
85. Rendón AL, Núñez M, Romero M, et al. Early monitoring of ribavirin plasma concentrations may predict anemia and early virologic response in HIV/hepatitis C virus-coinfected patients. J Acquir Immune Defic Syndr 2005, 39:401-405.
86. Aguilar Marucco D, Gonzalez de Requena D, Bonora S, et al. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon. J Antimicrob Chemother 2008, 61:919-924.
87. Nicot F, Legrand-Abravanel F, Lafont T, et al. Serum concentrations of ribavirin and pegylated interferon and viral responses in patients infected with HIV and HCV. J Med Virol 2008, 80:1523-1529.
88. Dahari H, Markatou M, Zeremski M, et al. Early ribavirin pharmacokinetics, HCV RNA and alanine aminotransferase kinetics in HIV/HCV co-infected patients during treatment with pegylated interferon and ribavirin. J Hepatol 2007, 47:23-30.
89. Piedoux S, Monnet E, Piroth L, et al. Relative impact of ribavirin monitoring and HIV coinfection on sustained virological response in patients with chronic hepatitis C. Antiviral Ther 2011, 16:1317-1326.
90. Kwo PY, Vinayek R The therapeutic approaches for hepatitis C virus: protease inhibitors and polymerase inhibitors. Gut Liver 2011, 5:406-417.